Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease.

Marilia Mastrocolla de Almeida Cardoso Juliana Rodrigues Machado Rúgolo Silvana Andrea Molina Lima Luís Gustavo Modelli de Andrade Daniel da Silva Pereira Curado Daniela Ponce

Published in: Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia (2022)

Intravenous paricalcitol has superior efficacy and similar safety to oral calcitriol, reducing the overall mortality of dialysis patients, although it implies a higher cost.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
high dose
ejection fraction
prognostic factors
cardiovascular events
risk factors
cardiovascular disease
coronary artery disease
replacement therapy
smoking cessation